Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: A translational investigation in the neoadjuvant gepartrio trial

Annals of Oncology

Volumn 24, Issue 11, 2013, Pages 2786-2793

  Denkert, C ^a   Loibl, S ^b   Muller B M ^a   Eidtmann, H ^c   Schmitt, W D ^a   Eiermann, W ^d   Gerber, B ^e   Tesch, H ^f   Hilfrich, J ^g   Huober, J ^h   Fehm, T ⁱ   Barinoff, J ^j   Jackisch, C ^k   Prinzler, J ^a   Rudiger T ^l   Erbstoßer E ^m   Blohmer, J U ⁿ   Budczies, J ^a   Mehta, K M ^b   von Minckwitz, G ^b,o  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b German Breast Group   (Germany)

^c UNIVERSITY OF KIEL   (Germany)

^d Gynecological Hospital Red Cross   (Germany)

^e Südstadt Clinic   (Germany)

^f Oncological Center   (Germany)

^g Department of Gynecology ^*  (Germany)

^h HEINRICH HEINE UNIVERSITY   (Germany)

ⁱ UNIVERSITY OF TÜBINGEN   (Germany)

^j UNIVERSITY HOSPITAL ESSEN   (Germany)

^k Klinikum Offenbach   (Germany)

^l Klinikum Karlsruhe   (Germany)

^m AMEOS Klinikum St Salvator   (Germany)

ⁿ MARTIN LUTHER KRANKENHAUS   (Germany)

^o GOETHE UNIVERSITY   (Germany)

more..

Author keywords

Breast cancer; Immunohistochemistry; Ki67; Neoadjuvant; Prediction; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE RECEPTOR; KI 67 ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; COHORT ANALYSIS; DISEASE FREE SURVIVAL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; TUMOR BIOPSY;

BREAST CANCER; IMMUNOHISTOCHEMISTRY; KI67; NEOADJUVANT; PREDICTION; PROGNOSIS;

ADULT; BIOPSY; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; MIDDLE AGED; NEOADJUVANT THERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 84887042578     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt350     Document Type: Article

References (18)

1. Gerdes J, Schwab U, Lemke H et al. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983; 31: 13-20.
2. Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 2005; 23: 7212-7220.
3. de Azambuja E, Cardoso F, de Castro G, Jr et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer 2007; 96: 1504-1513.
4. Yerushalmi R, Woods R, Ravdin PM et al. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 2010; 11: 174-183.
5. Stuart-Harris R, Caldas C, Pinder SE et al. Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. Breast 2008; 17: 323-334.
6. Luporsi E, André F, Spyratos F et al. Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. Breast Cancer Res Treat 2012; 132: 895-915.
7. Goldhirsch A, Wood WC, Coates AS et al. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011; 22: 1736-1747.
8. Goldhirsch A, Ingle JN, Gelber RD et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009; 20: 1319-1329.
9. Dowsett M, Nielsen TO, A'Hern R et al. International Ki-67 in Breast Cancer Working Group. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst 2011; 103: 1656-1664.
10. Budczies J, Klauschen F, Sinn BV et al. Cutoff finder: a comprehensive and straightforward web application enabling rapid biomarker cutoff optimization. PLOS One 2012; 7: e51862 http://molpath.charite.de/cutoff.
11. von Minckwitz G, Schmitt WD, Loibl S et al. Ki67 measured after neoadjuvant chemotherapy for primary breast cancer. Clin Cancer Res 2013 June 27 [Epub ahead of print]. PubMed PMID: 23812670.
12. Inwald EC, Klinkhammer-Schalke M, Hofstädter F et al. Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. Breast Cancer Res Treat 2013; 139(2): 539-552.
13. Fasching PA, Heusinger K, Haeberle L et al. Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. BMC Cancer 2011; 11: 486.
14. Dowsett M, Smith IE, Ebbs SR et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 2007; 99: 167-170.
15. Dowsett M, Smith IE, Ebbs SR et al. Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res 2005; 11: 951s-958s.
16. Nielsen TO, Polley M-YC, Leung SCY et al. An International Ki67 Reproducibility Study. Proc SABCS 2012 Abstract S4-S6.
17. Varga Z, Diebold J, Dommann-Scherrer C et al. How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss Working Group of Breast- and Gynecopathologists. PLoS One 2012; 7: e37379.
18. Hatzis C, Pusztai L, Valero V et al. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA 2011; 305: 1873-1881.